secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2022-01-26T23:59:59+00:00
Accession:  0001193125-22-018422
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara sells cell therapy manufacturing facility to Fujifilm for $100M; preliminary cash $371.1M
--------------------------------------------------------------------------------

- Fujifilm to acquire ATOM facility for $100M upfront; closing expected April 2022.
- Preliminary cash, equivalents & short-term investments of $371.1M as of Dec 31, 2021.
- Transaction plus existing cash expected to fund planned operations into Q4 2023.
- COO Joseph Newell transitions to consultant effective Jan 31, 2022; receives severance of 12 months' salary.
- Parties enter long-term supply agreement (up to 10 years) for clinical/commercial manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312522018422/0001193125-22-018422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312522018422/d607690d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-018422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer